ArticlePloS one2012
Development and validation of Burkholderia pseudomallei-specific real-time PCR assays for clinical, environmental or forensic detection applications.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 136 citations in OpenAlex.
- Current Melioidosis Diagnostic Landscape and Missed Opportunities in Biomarker Development.Diagnostics (Basel, Switzerland) · 2026Review
- Evaluation of culture- and PCR-based methods for detecting Burkholderia pseudomallei in soil samples in Thailand.PLoS neglected tropical diseases · 2026Article
- Stability assessment of whole cell ELISA for Burkholderia pseudomallei antibodies detection.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- A Novel Virulent Clinical Isolate of Burkholderia pseudomallei Imported from Thailand Exhibiting Resistance to Trimethoprim-Sulfamethoxazole.The American journal of tropical medicine and hygiene · 2025Article
- Virulome and phylogenomic profiling of a novel Burkholderia pseudomallei strain from an Indian clinical isolate.Molecular genetics and genomics : MGG · 2024Article
- Genome sequence of two novel virulent clinical strains of Burkholderia pseudomallei isolated from acute melioidosis cases imported to Israel from India and Thailand.BMC genomic data · 2024Article
- Development of a novel sequence based real-time PCR assay for specific and sensitive detection of Burkholderia pseudomallei in clinical and environmental matrices.Annals of clinical microbiology and antimicrobials · 2024Article
- Development of a Novel Internally Controlled HrpB1 Gene-Based Real-Time qPCR Assay for Detection of Burkholderia pseudomallei.Molecular diagnosis & therapy · 2024Article
- Highly specific and sensitive detection of Burkholderia pseudomallei genomic DNA by CRISPR-Cas12a.PLoS neglected tropical diseases · 2022Article
- Examining the genomic features of human and plant-associated Burkholderia strains.Archives of microbiology · 2022Article
- Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2022Article
- Genomic diversity and antimicrobial resistance ofMicrobial genomics · 2022Article
- Environmental Factors Associated With Soil Prevalence of the Melioidosis PathogenFrontiers in microbiology · 2022Article
- Loop-Mediated Isothermal Amplification (LAMP) Assay for DetectingPathogens (Basel, Switzerland) · 2021Article
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Quantification of DNA through the NanoDrop Spectrophotometer: Methodological Validation Using Standard Reference Material and Sprague Dawley Rat and Human DNA.International journal of analytical chemistry · 2020Article
- Vaginal Microbiota Evaluation and Lactobacilli Quantification by qPCR in Pregnant and Non-pregnant Women: A Pilot Study.Frontiers in cellular and infection microbiology · 2020Article
- Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogenMicrobial genomics · 2019Article
- Case Report: Imported Melioidosis from Goa, India to Israel, 2018.The American journal of tropical medicine and hygiene · 2019Article
- Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei.Microbiology resource announcements · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 5 countries.
Funding
Abstract
The bacterium Burkholderia pseudomallei causes melioidosis, a rare but serious illness that can be fatal if untreated or misdiagnosed. Species-specific PCR assays provide a technically simple method for differentiating B. pseudomallei from near-neighbor species. However, substantial genetic diversity and high levels of recombination within this species reduce the likelihood that molecular signatures will differentiate all B. pseudomallei from other Burkholderiaceae. Currently available molecular assays for B. pseudomallei detection lack rigorous validation across large in silico datasets and isolate collections to test for specificity, and none have been subjected to stringent quality control criteria (accuracy, precision, selectivity, limit of quantitation (LoQ), limit of detection (LoD), linearity, ruggedness and robustness) to determine their suitability for environmental, clinical or forensic investigations. In this study, we developed two novel B. pseudomallei specific assays, 122018 and 266152, using a dual-probe approach to differentiate B. pseudomallei from B. thailandensis, B. oklahomensis and B. thailandensis-like species; other species failed to amplify. Species specificity was validated across a large DNA panel (>2,300 samples) comprising Burkholderia spp. and non-Burkholderia bacterial and fungal species of clinical and environmental relevance. Comparison of assay specificity to two previously published B. pseudomallei-specific assays, BurkDiff and TTS1, demonstrated comparable performance of all assays, providing between 99.7 and 100% specificity against our isolate panel. Last, we subjected 122018 and 266152 to rigorous quality control analyses, thus providing quantitative limits of assay performance. Using B. pseudomallei as a model, our study provides a framework for comprehensive quantitative validation of molecular assays and provides additional, highly validated B. pseudomallei assays for the scientific research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.